Hepatitis B and hepatitis C viruses in liver transplantation.
Liver transplantation (LT) for end-stage liver disease (ESLD) secondary to hepatitis viruses has evolved rapidly during the last two decades. ESLD secondary to hepatitis C virus (HCV) accounts for approximately 50% of LT in the United States and Europe. Despite the decrease in the number of new HCV infections, the prevalence of advanced HCV-related liver disease is steadily increasing. In light of the near universal recurrence of posttransplantation HCV infection and our limited ability to treat recurrent disease, transplantation is in danger of being overrun by viral hepatitis, unless effective strategies can be used to treat disease, expand the donor pool of available organs, and prevent disease recurrence. In the early 1980s, results of LT for chronic hepatitis B virus infection were hampered by recurrent infection and subsequent allograft failure. However, with the introduction of passive immunoprophylaxis with hepatitis B immunoglobulin and treatment with potent nucleoside analogs, there has been a resurgence of LT for hepatitis B virus-related ESLD. Despite the wide acceptance of LT as a therapy for ESLD, there is little consensus on the appropriate immunosuppressive regimens, and prophylactic and therapeutic treatments vary widely from one center to another. This review summarizes available data and highlights appropriate strategies to improve outcomes.
Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA. mcurry@bidmc.harvard.edu
Michael P
MP
Curry
D006509:Hepatitis B / Q000601:surgery*; D006526:Hepatitis C / Q000601:surgery*; D006801:Humans; D007136:Immunoglobulins / Q000627:therapeutic use; D007165:Immunosuppression Therapy; D019259:Lamivudine / Q000627:therapeutic use; D016031:Liver Transplantation; D012086:Reoperation; D014611:Vaccination
D007136:Immunoglobulins; D019259:Lamivudine; C045213:hepatitis B hyperimmune globulin